European Archives - Page 802 of 1275 - European Medical Journal

AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study

AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukaemia and an IDH1 Mutation

Isocitrate dehydrogenase 1 (IDH1) is a metabolic enzyme which catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate…

hematology 8.1 featured image

Implementation of Haematological Malignancies Patient-Reported Outcome Measure in Clinical Practice: Haematologists’ Experience

Patients with haematological malignancies (HM) may experience significantly compromised quality of life (QoL) as a result of the disease and its…

hematology 8.1 featured image

Integrative Analysis of the Genomic Landscape of Hodgkin Lymphoma Using Liquid Biopsies

The genomic landscape of Hodgkin lymphoma (HL) is not well understood because of the scarcity of Hodgkin-Reed–Sternberg cells, which makes conventional…

Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib

Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib, with the BCL2-Inhibitor Venetoclax +/-Azacitidine in IDH1-Mutated Myeloid Malignancies

Venetoclax is a potent, selective, oral inhibitor of B-cell lymphoma-2. It is approved in the USA in combination with azacitidine, decitabine…

hematology 8.1 featured image

Mechanistic Insights into the Inhibition of Regulatory T Cells by Dasatinib in Chronic Myeloid Leukaemia Patients with Clonal Lymphocytosis

Dasatinib is a potent inhibitor of lymphocyte-specific protein tyrosine kinase (Lck), which plays a pivotal role in T-cell receptor (TCR) signalling…

hematology 8.1 featured image

Pregnancy-Related Thromboembolism in Sickle Cell Disease

Haematological disorders are predominant in the tropical and subtropical countries where major problems of sickle-cell disease (SCD) and thalassaemias…

hematology 8.1 featured image

Identification of HIF2α as a Novel Determinant of Acute Myeloid Leukaemia Block of Differentiation Poses its Inhibition as a Potential Therapeutic Opportunity for Acute Myeloid Leukaemia Patients

Signalling via hypoxia inducible factors (HIF)1α and HIF2α is importantly implicated in cancer,1 although it has been predominantly studied in solid…

Initial Anticoagulant Management of Deep Vein Thrombosis

Anticoagulant Management of Deep Vein Thrombosis: Review of Current Approaches

The initial management of deep vein thrombosis is starting to happen in general practice.

hematology 8.1 featured image

Comparison of Decitabine with Venetoclax versus Intensive Chemotherapy Using Propensity Score Matching and Treatment-related Mortality Risk Scoring

Acute myeloid leukaemia (AML) usually presents in older patients over the age of 65 years.1 A large proportion of such patients are frail or have…

hematology 8.1 featured image

Concerns Regarding the Management of β-Thalassaemia Patients in the Era of COVID-19

Many cases of pneumonia clustered in the city of Wuhan, China, were reported in December 2019, and source tracing has showed Huanan Seafood Market, Wuhan, China, as the origin.